FDA Determines Regulatory Review Period for FYCOMPA Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for FYCOMPA, a human drug product, following a patent extension application submitted to the U.S. Patent and Trademark Office.